5 Things Investors Need to Know About Friday's Markets

After major indexes plunged Thursday, Nasdaq 100 futures were recently up more than 1%, while Dow futures were down nearly 1%. Some AI-related stocks that fell Thursday were among the morning’s biggest gainers, though bearish sentiment toward AI could affect Anthropic’s planned IPO. Hiring last month exceeded expectations, and Moderna shares climbed as investors welcomed its results and outlook.

Analysis

The Nasdaq rebound alongside Dow weakness looks more like a positioning and duration trade than evidence that AI fundamentals have reset. Stronger hiring can support earnings expectations while also keeping rate-sensitive growth multiples under pressure; the missing discriminator is the rates response. If Treasury yields rise, an intraday AI bounce is vulnerable even if employment data is healthy. Over the next 1–3 months, persistent AI skepticism could lower the valuation ceiling for private-market peers and make Anthropic’s IPO pricing and timing more sensitive to public-market comparables. That is a sentiment and financing-window risk, not evidence by itself of weaker AI demand. For public AI infrastructure exposures, watch whether spending and guidance weaken; sentiment alone is a weaker signal than capex revisions.

Moderna’s positive reaction may reflect improved expectations, but the article gives no product-level results or guidance detail to establish durability. A sustained rerating requires evidence that outlook translates into repeatable revenue and cash generation; otherwise the move risks fading as investors reassess biotech pipeline and commercialization uncertainty. Near term, futures and rates can dominate single-name fundamentals. Over 6–18 months, AI valuation dispersion and Moderna’s delivery against guidance matter more. No valuation, earnings detail, or price levels are supplied, so conviction trades and numeric targets are unwarranted.

Key Decisions for Investors

• Avoid chasing the Nasdaq futures bounce at the open. Treat QQQ versus DIA as a tactical relative-value watch: favor QQQ only if Treasury yields are stable or falling and AI breadth holds through the session; rising yields with renewed AI underperformance would falsify that setup.
• Keep Anthropic’s IPO as a window-risk alert, not a trade in ANT: verify whether the offering proceeds, its pricing versus public AI/software comparables, and whether public-market weakness changes the timetable. A delayed or discounted deal would be a negative read-through for private AI valuations, not automatically for AI demand.
• For Moderna, wait for the underlying results and outlook details before adding to the rally. Track guidance revisions and evidence of durable product revenue; a subsequent outlook cut or failure to convert guidance into revenue would challenge the positive price reaction.
• Reassess over the next 1–3 months using Treasury yields, QQQ/DIA relative performance, AI-company capex or guidance revisions, and Moderna’s reported performance against its outlook; absent confirmation, there may be no compelling trade.